The sales of Renin-Angiotensin System medicines in Canada are projected to decline steadily from 2024 to 2028. Starting at 881.3 million CAD in 2024, the sales are expected to decrease to 739.8 million CAD by 2028. Compared to 2023, the inferred trend indicates a persistent reduction in sales, highlighting a potential concern or market shift within this pharmaceutical segment.

Future trends to watch for include:

Potential introduction of more effective or generic alternatives, further driving down sales.
Healthcare policy changes that may impact medicine accessibility and pricing.
Changing demographics and disease prevalence impacting demand.

Download as XLS

More about Antihypertensive Industry 2025-2029